Last reviewed · How we verify
Dapsone 5.0% Gel (Allergan)
Dapsone is a sulfone antibiotic that inhibits bacterial dihydropteroate synthase and has anti-inflammatory properties through suppression of neutrophil function and reactive oxygen species production.
Dapsone is a sulfone antibiotic that inhibits bacterial dihydropteroate synthase and has anti-inflammatory properties through suppression of neutrophil function and reactive oxygen species production. Used for Acne vulgaris (topical gel formulation).
At a glance
| Generic name | Dapsone 5.0% Gel (Allergan) |
|---|---|
| Also known as | Active Comparator |
| Sponsor | Seegpharm S.A. |
| Drug class | Sulfone antibiotic with anti-inflammatory properties |
| Target | Dihydropteroate synthase (bacterial); neutrophil function and ROS production (host) |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | Phase 3 |
Mechanism of action
Dapsone works through dual mechanisms: as an antimicrobial agent targeting bacterial folate synthesis, and as an anti-inflammatory agent that suppresses neutrophil-mediated inflammation. In topical gel formulation for acne, it primarily leverages its anti-inflammatory and antimicrobial properties to reduce acne lesions and associated inflammation.
Approved indications
- Acne vulgaris (topical gel formulation)
Common side effects
- Application site erythema
- Application site dryness
- Application site irritation
- Oiliness/seborrhea
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Dapsone 5.0% Gel (Allergan) CI brief — competitive landscape report
- Dapsone 5.0% Gel (Allergan) updates RSS · CI watch RSS
- Seegpharm S.A. portfolio CI